- Home
- HTO vs VERA Comparison
HTO vs VERA Comparison
Compare HTO & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTO
- VERA
- Stock Information
- Founded
- HTO 1985
- VERA 2016
- Country
- HTO United States
- VERA United States
- Employees
- HTO N/A
- VERA N/A
- Industry
- HTO Water Supply
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- HTO Utilities
- VERA Health Care
- Exchange
- HTO Nasdaq
- VERA Nasdaq
- Market Cap
- HTO 1.7B
- VERA 1.4B
- IPO Year
- HTO N/A
- VERA 2021
- Fundamental
- Price
- HTO $49.80
- VERA $21.27
- Analyst Decision
- HTO Hold
- VERA Buy
- Analyst Count
- HTO 1
- VERA 8
- Target Price
- HTO $58.00
- VERA $64.29
- AVG Volume (30 Days)
- HTO 242.4K
- VERA 1.2M
- Earning Date
- HTO 07-28-2025
- VERA 08-05-2025
- Dividend Yield
- HTO 3.37%
- VERA N/A
- EPS Growth
- HTO 12.08
- VERA N/A
- EPS
- HTO 3.05
- VERA N/A
- Revenue
- HTO $788,737,000.00
- VERA N/A
- Revenue This Year
- HTO $6.23
- VERA N/A
- Revenue Next Year
- HTO $5.34
- VERA N/A
- P/E Ratio
- HTO $16.36
- VERA N/A
- Revenue Growth
- HTO 12.40
- VERA N/A
- 52 Week Low
- HTO $44.91
- VERA $18.53
- 52 Week High
- HTO $61.97
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- HTO N/A
- VERA 48.60
- Support Level
- HTO N/A
- VERA $19.07
- Resistance Level
- HTO N/A
- VERA $22.74
- Average True Range (ATR)
- HTO 0.00
- VERA 0.97
- MACD
- HTO 0.00
- VERA 0.13
- Stochastic Oscillator
- HTO 0.00
- VERA 59.99
About HTO H2O America Common Stock
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.